Abstract：
Lamivudine (3TC)/dolutegravir (DTG) single tablet regimen (STR) has shown long-term efficacy and tolerability in people living with HIV (PLWH). Dolutegravir has been approved for use in children, while data on the efficacy of 3TC plus DTG in maintaining virological suppression in this population are still under evaluation. In this case series, we describe three children with perinatally acquired HIV who maintained virological suppression after switching antiretroviral therapy to DTG/3TC. We present three case reports of three children enrolled in the Italian Register for HIV Infection in Children: a 9-year-old boy, a 10-year-old girl, and a 2-year-old girl with perinatally acquired HIV who immediately started antiretroviral therapy with a three-drug regimen upon diagnosis, which occurred at delivery, after 6 months of life, and after 2 years of life, respectively. They achieved and maintain virological suppression after 1, 6, and 7 months of therapy, respectively; then a switch strategy was performed with a two-drug regimen with DTG/3TC STR at the age of 7 years for the first child and at the age of 9 years for the second, while the third was switched to a DTG plus 3TC not STR, owing to weight requirements, at the age of 2 years and 10 months. All children maintained virological suppression at last follow-up visit (January 2024), showing an excellent growth curve and maintaining good adherence and tolerability to DTG plus 3TC. A two-drug regimen with DTG/3TC demonstrated efficacy in maintaining virological suppression in a switch strategy in these children, with important advantages such as better tolerability and comfort of taking a single tablet once daily.
摘要：
拉米夫定（3TC）/dolutegravir（DTG）单片方案（STR）在HIV感染者（PLWH）中显示出长期疗效和耐受性。Dolutegravir已被批准用于儿童，而关于3TC加DTG在维持该人群病毒学抑制方面的功效的数据仍在评估中。在这个系列中,我们描述了3名围生期获得性HIV患儿,他们在将抗逆转录病毒治疗转换为DTG/3TC后仍保持病毒学抑制.我们提供了三份病例报告，其中三名儿童登记在意大利儿童艾滋病毒感染登记册中：一名9岁男孩，一个10岁的女孩,一名2岁女孩围产期感染艾滋病毒，诊断后立即开始使用三药方案进行抗逆转录病毒治疗，发生在交货时，在六个月的生命之后，在2年的生命之后,分别。他们在治疗1、6和7个月后实现并维持病毒学抑制，分别；然后在第一个孩子的7岁和第二个孩子的9岁时，采用DTG/3TCSTR的两种药物方案进行转换策略，当第三个被切换到DTG加3TC而不是STR时，由于重量要求，在2岁零10个月的年龄。所有儿童在最后一次随访（2024年1月）时保持病毒学抑制，显示出优异的生长曲线，并保持良好的粘附性和对DTG加3TC的耐受性。DTG/3TC的双药方案在这些儿童的转换策略中显示出维持病毒学抑制的功效。具有重要的优点，例如更好的耐受性和每天服用一次的舒适。
